These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. JAK1 and Tyk2 activation by the homologous polycythemia vera JAK2 V617F mutation: cross-talk with IGF1 receptor. Staerk J; Kallin A; Demoulin JB; Vainchenker W; Constantinescu SN J Biol Chem; 2005 Dec; 280(51):41893-9. PubMed ID: 16239216 [TBL] [Abstract][Full Text] [Related]
3. Three Tyrosine Residues in the Erythropoietin Receptor Are Essential for Janus Kinase 2 V617F Mutant-induced Tumorigenesis. Ueda F; Tago K; Tamura H; Funakoshi-Tago M J Biol Chem; 2017 Feb; 292(5):1826-1846. PubMed ID: 27998978 [TBL] [Abstract][Full Text] [Related]
4. JAK2 V617F stimulates proliferation of erythropoietin-dependent erythroid progenitors and delays their differentiation by activating Stat1 and other nonerythroid signaling pathways. Shi J; Yuan B; Hu W; Lodish H Exp Hematol; 2016 Nov; 44(11):1044-1058.e5. PubMed ID: 27473563 [TBL] [Abstract][Full Text] [Related]
5. Aberrant signal transduction pathways in myeloproliferative neoplasms. Kota J; Caceres N; Constantinescu SN Leukemia; 2008 Oct; 22(10):1828-40. PubMed ID: 18769448 [TBL] [Abstract][Full Text] [Related]
6. A unique activating mutation in JAK2 (V617F) is at the origin of polycythemia vera and allows a new classification of myeloproliferative diseases. Vainchenker W; Constantinescu SN Hematology Am Soc Hematol Educ Program; 2005; ():195-200. PubMed ID: 16304380 [TBL] [Abstract][Full Text] [Related]
7. The first international meeting on V617F JAK2 mutation and its relevance in Philadelphia-negative myeloproliferative disorders. Kiladjian JJ; Casadevall N; Vainchenker W; Fenaux P Pathol Biol (Paris); 2007 Mar; 55(2):85-7. PubMed ID: 16901656 [TBL] [Abstract][Full Text] [Related]
9. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation]. Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211 [TBL] [Abstract][Full Text] [Related]
10. Akt activation through the phosphorylation of erythropoietin receptor at tyrosine 479 is required for myeloproliferative disorder-associated JAK2 V617F mutant-induced cellular transformation. Kamishimoto J; Tago K; Kasahara T; Funakoshi-Tago M Cell Signal; 2011 May; 23(5):849-56. PubMed ID: 21255641 [TBL] [Abstract][Full Text] [Related]
11. Activating JAK2 mutants reveal cytokine receptor coupling differences that impact outcomes in myeloproliferative neoplasm. Yao H; Ma Y; Hong Z; Zhao L; Monaghan SA; Hu MC; Huang LJ Leukemia; 2017 Oct; 31(10):2122-2131. PubMed ID: 28057939 [TBL] [Abstract][Full Text] [Related]
12. HLA-G turns off erythropoietin receptor signaling through JAK2 and JAK2 V617F dephosphorylation: clinical relevance in polycythemia vera. Menier C; Guillard C; Cassinat B; Carosella ED; Rouas-Freiss N Leukemia; 2008 Mar; 22(3):578-84. PubMed ID: 18059484 [TBL] [Abstract][Full Text] [Related]
13. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. Pikman Y; Lee BH; Mercher T; McDowell E; Ebert BL; Gozo M; Cuker A; Wernig G; Moore S; Galinsky I; DeAngelo DJ; Clark JJ; Lee SJ; Golub TR; Wadleigh M; Gilliland DG; Levine RL PLoS Med; 2006 Jul; 3(7):e270. PubMed ID: 16834459 [TBL] [Abstract][Full Text] [Related]
14. Tyk2 mutation homologous to V617F Jak2 is not found in essential thrombocythaemia, although it induces constitutive signaling and growth factor independence. Shide K; Shimoda K; Kamezaki K; Kakumitsu H; Kumano T; Numata A; Ishikawa F; Takenaka K; Yamamoto K; Matsuda T; Harada M Leuk Res; 2007 Aug; 31(8):1077-84. PubMed ID: 17011030 [TBL] [Abstract][Full Text] [Related]
15. Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F. Zaleskas VM; Krause DS; Lazarides K; Patel N; Hu Y; Li S; Van Etten RA PLoS One; 2006 Dec; 1(1):e18. PubMed ID: 17183644 [TBL] [Abstract][Full Text] [Related]
16. The JAK2(V617F) tyrosine kinase mutation in myeloproliferative disorders: Summary of published literature and a perspective. Wadleigh M; Gilliland DG Curr Hematol Malig Rep; 2006 Jun; 1(2):75-80. PubMed ID: 20425335 [TBL] [Abstract][Full Text] [Related]
17. STAT5 activation is critical for the transformation mediated by myeloproliferative disorder-associated JAK2 V617F mutant. Funakoshi-Tago M; Tago K; Abe M; Sonoda Y; Kasahara T J Biol Chem; 2010 Feb; 285(8):5296-307. PubMed ID: 20028972 [TBL] [Abstract][Full Text] [Related]
18. The 2001 World Health Organization and updated European clinical and pathological criteria for the diagnosis, classification, and staging of the Philadelphia chromosome-negative chronic myeloproliferative disorders. Michiels JJ; De Raeve H; Berneman Z; Van Bockstaele D; Hebeda K; Lam K; Schroyens W Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):307-40. PubMed ID: 16810609 [TBL] [Abstract][Full Text] [Related]
19. Thrombopoietin receptor down-modulation by JAK2 V617F: restoration of receptor levels by inhibitors of pathologic JAK2 signaling and of proteasomes. Pecquet C; Diaconu CC; Staerk J; Girardot M; Marty C; Royer Y; Defour JP; Dusa A; Besancenot R; Giraudier S; Villeval JL; Knoops L; Courtoy PJ; Vainchenker W; Constantinescu SN Blood; 2012 May; 119(20):4625-35. PubMed ID: 22378845 [TBL] [Abstract][Full Text] [Related]
20. The JAK kinase inhibitor CP-690,550 suppresses the growth of human polycythemia vera cells carrying the JAK2V617F mutation. Manshouri T; Quintás-Cardama A; Nussenzveig RH; Gaikwad A; Estrov Z; Prchal J; Cortes JE; Kantarjian HM; Verstovsek S Cancer Sci; 2008 Jun; 99(6):1265-73. PubMed ID: 18482053 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]